Is BridgeBio Pharma, Inc. (BBIO) halal? Doubtful. Based on AAOIFI screening, BridgeBio Pharma, Inc. passes the business activity screen but has financial ratios approaching AAOIFI limits with a compliance score of 56/100 (Grade: C+).
BBIO — Is BridgeBio Pharma, Inc. Halal?
DoubtfulBridgeBio Pharma, Inc.
$63.88
-2.26%
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
Sector: Healthcare · Industry: Biotechnology
Why This Stock Is Doubtful
- Non-compliant income is 4.6% of revenue — only 0.4 points below the 5% limit
Stocks are marked Doubtful when financial ratios pass but approach AAOIFI thresholds. Consider consulting a qualified scholar for a definitive ruling.
Shariah Compliance Status
Based on AAOIFI screening standards
Fair
Some financial ratios approaching limits
Business Activity Screen
PassedChecks if the business is involved in prohibited activities (alcohol, gambling, pork, conventional banking, etc.)
Financial Ratio Screen
PassedFinancial ratios must be below AAOIFI thresholds
Compliance History
Doubtfulnow
since Jun 2026
Not Halal
until the change above
Tracked since May 2026. Updates automatically on each re-screen.
Purify Your BBIO Dividends
4.6% non-compliant incomeBBIO has 4.6% prohibited income. Calculate exactly how much of your dividends to donate.
Financial Overview
Market Cap
12.5B
Price
$63.88
Sector
Healthcare
Industry
Biotechnology
More Healthcare Stocks
Track BBIO and 10,000+ stocks with AI insights
Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.
Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.